Effects of carfilzomib alone and in combination with cisplatin on the gene expression of Bcl-2 and Bax in ovarian carcinoma cell lines

Background: Carfilzomib (CFZ), a proteasome inhibitor, has demonstrated potential in the treatment of ovarian cancer, including variants that are resistant to cisplatin (Cis).Objectives: This study aims to evaluate the effects of CFZ, both as a monotherapy and in combination with Cis, on the express...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Alireza Saedi, Javad Zavar Reza, Navid Ghasemzadeh, Moein Moradi, Behnaz Majidi, Amir Hossein Fatehi Marj, Sadegh Zarei
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Sadra Danesh Negar 2025-03-01
Schriftenreihe:	Journal of Preventive and Complementary Medicine
Schlagworte:	carfilzomib cisplatin ovarian cancer bcl-2 bax apoptosis
Online-Zugang:	https://www.jpcmed.com/article_216399_bd98847953a15ea8020a3ebd5742c2b6.pdf
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!